Low-dose (0.2 mg/day) and standard-dose (0.4 mg/day) tamsulosin were studied in a randomized controlled trial of 75 outpatients with distal ureteroliths in Thailand. Group 1 (n = 25; control) received oral sodium diclofenac 50 mg twice a day for 10 days; group 2 (n = 25) received oral sodium diclofenac 50 mg twice a day for 10 days, with oral tamsulosin 0.2 mg once a day up to 28 days; and group 3 (n = 25) received oral sodium diclofenac 50 mg twice a day for 10 days, with oral tamsulosin 0.4 mg once a day up to 28 days. For groups 1, 2 and 3, respectively, the expulsion rates were 4%, 40% and 68% (significantly different for group 1 vs group 2, and for group 1 vs group 3) and mean expulsion times were 23.00, 9.30 and 10.76 days. Both doses of tamsulosin increased stone expulsion rate and decreased expulsion time in comparison with the control, and have been shown to be safe and effective in Asian patients.
Introduction
Treatments for ureteric stones traditionally include watchful waiting, extracorporeal shock wave lithotripsy, ureteroscopy and open ureterolithotomy. Minimally invasive techniques, such as shock wave lithotripsy and endourology, are now being used more frequently. Even minimally invasive surgery, however, is not free of complications and the cost is high. 1 Stone size and location are the main factors that can influence their passage; a stone smaller than 4 mm is usually passed after conservative treatment. 1 The human ureter contains a high number of α-adrenergic receptors, especially α 1d -receptors at the lower part of the ureter. 2, 3 Tamsulosin is a combined α 1a -and α 1dselective adrenergic antagonist that is an alternative to other medications, such as calcium channel blockers, corticosteroids, and analgesic and anti-inflammatory drugs, for the treatment of distal ureteric stones. The standard dose of tamsulosin for the treatment of distal uretic stones is 0.4 B Lojanapiwat, W Kochakarn, N Suparatchatpan et al.
Tamsulosin for distal ureteroliths mg/day; many reports from Asian countries have confirmed that low-dose tamsulosin (0.2 mg/day) is effective in the treatment of benign prostatic hyperplasia (BPH). 4 -6 The present study was, therefore, carried out to compare the ureterolith expulsion rate and expulsion time after administration of low-dose (0.2 mg/day) or standard-dose (0.4 mg/day) tamsulosin against a control (sodium diclofenac) in the adjunctive medical treatment of distal ureteric stones. Diclofenac was chosen as the control because it is used for promoting stone passage and controlling pain in the early period of treatment.
Patients and methods

PATIENTS AND STUDY DESIGN
This randomized controlled study to measure the effectiveness of tamsulosin in treating distal ureteric stones was approved by the ethics committees of Chiangmai University, Ramathibodi Hospital and Maharat Nakornratchasima Hospital. Patients of the above-mentioned institutions who had distal ureteric stones of 4 -10 mm, measured by plain kidney, ureter and bladder radiographs (plain KUB) (maximum length plus maximum width divided by two), gave their informed written consent and were interviewed prior to taking part in the study.
The exclusion criteria, decided before the interviews had been held, were urinary tract infection, severe hydronephrosis (marked dilatation of the collecting system) or a history of ureteric surgery. Eligible patients were enrolled from 10 January to 9 July 2006. The required sample size was estimated by two proportions as described in a previous report 1 and was calculated as being sufficient to detect significance between the control versus low-dose or the control versus standard-dose treatments.
The patients were block randomized into three groups by the assistant nurse. The investigators knew the patients in each of the groups before the start of the intervention. Before the treatment, urinalysis, blood urea nitrogen (BUN), creatinine levels, plain KUB, intravenous pyelography and/or ultrasound views of the kidney, ureter and bladder were obtained for all patients. Plain KUB was performed at days 14 and 28 or on the day on which the stone was passed.
TREATMENTS AND MONITORING
Group 1 (control) received sodium diclofenac (Voltraren ® ; Novartis, Origgio, Italy), 50 mg twice a day for 10 days. Group 2 received sodium diclofenac as group 1, plus tamsulosin (Harnal ® ; Astellas Pharma, Tokyo, Japan), 0.2 mg once a day for a maximum of 28 days or until the ureterolith was passed. Group 3 received sodium diclofenac as group 1, plus tamsulosin, 0.4 mg once a day for a maximum of 28 days or until the ureterolith was passed. All treatments were administered orally. If patients developed renal colic during the treatment, they were given an intramuscular injection of 75 mg sodium diclofenac in the emergency department. All patients were asked the same questions about symptoms and side-effects. On the day of stone expulsion, the number of sodium diclofenac injections and any side-effects of the medications were recorded. The criteria for discontinuing the medication were uncontrolled pain, urinary tract infection, unsuccessful expulsion after 28 days, and the patient's desire to have the stone removed before the end of the study.
STATISTICAL ANALYSIS
Statistical analysis with the χ 2 and Mann-Whitney tests was performed. A Pvalue < 0.05 was considered to be statistically significant.
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Results
Ninety patients, who had distal ureteric stones from 4 to 10 mm in size, were interviewed. Fifteen patients were subsequently excluded and the remaining 75 were enrolled in the study and randomly allocated to one of the three groups (25 patients per group).
All patients tolerated the medications well. Only one patient in group 2 needed an intramuscular injection of dicofenac in the emergency department. None of the patients in groups 2 or 3 had hypotension or retrograde ejaculation.
All patients who had stones remaining after the end of the 28-day study period were successfully treated with ureteroscopy without complication, except for one patient from group 2 who underwent extracorporeal shock wave lithotripsy.
BASELINE DATA
All patients were free of urinary tract infection, severe hydronephrosis (marked dilatation of the collecting system), elevated serum creatinine levels, diabetes and peptic ulcer disease, and had no history of passing stones or ureteric surgery. The mean ages of the patients were 46.52, 48.00 and 46.71 years, the mean weights were 65.40, 66.40 and 66.20 kg, and the mean sizes of the stones were 6.70, 6.42 and 6.26 mm in groups 1, 2 and 3, respectively.
OUTCOMES AND ESTIMATION
Successful treatment, defined as passing the stone, occurred in 4% of patients in group 1 (1/25 patients), 40% in group 2 (10/25 patients), and 68% in group 3 (17/25 patients) ( Table 1) and was significant (P < 0.001) between group 1 (control) and group 2 (low dose), and between group 1 (control) and group 3 (standard dose), but not between group 2 (low dose) and group 3 (standard dose). The mean times to pass the stones were 23.00, 9.30 and 10.76 days in groups 1, 2 and 3, respectively, which was significant (P < 0.001) between group 1 (control) and group 2 (low dose), and between group 1 (control) and group 3 Table 2 . The expulsion rate and rate of ureterorenoscopy were significantly different between groups 1 (control) and 2 (low dose) (P = 0.006 and P = 0.006 respectively), and between groups 1 (control) and 3 (standard dose) (P < 0.001 and P < 0.0001 respectively), but not between groups 2 (low dose) and 3 (standard dose). Expulsion time was significantly different between all three groups, as shown in Table 2 .
No adverse events of hypotension were reported for any of the patients enrolled in the study. There were no differences in renal colic episodes between the three groups and no patient complained of retrograde ejaculation.
Discussion
Ureteroliths account for 20% of all urinary tract stones and 70% of these are located in the distal portion of the ureter. Renal colic leads to significant morbidity for patients who have ureteric stones, especially those with stones at the distal portion of the ureter. Treatments for distal ureteric stones include watchful waiting, extracorporeal shock wave lithotripsy, ureteroscopy and open ureterolithotomy. If possible, watchful waiting should be the first choice of treatment because it is not invasive and has the lowest cost. Some complications may occur during watchful waiting, such as urinary tract infection, hydronephrosis and repeated renal colic. The conditions appropriate for medical treatment include sterile urine and no significant hydronephrosis. No differences in renal colic episodes occurred between the three groups in the present study and no patient complained of retrograde ejaculation, which may be due to the short duration of tamsulosin treatment and/or a possible decrease or absence of coitus due to renal pain.
Low-dose (0.2 mg) and standard-dose (0.4 mg) tamsulosin were found to be effective in treating distal ureteric stones in the Asian patients studied in the present trial. There were some indications that the standarddose tamsulosin might be more beneficial; for example its higher stone expulsion rate of 68% versus 40%. However, these rates 
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were not significantly different and the sample size was too small for the results to be considered conclusive, indicating the need to conduct a second trial with a larger sample size. There was no significant difference in the time taken to pass the stone: 9.30 versus 10.76 days for the low and standard doses, respectively. Although the comparisons between the doses are not conclusive because of the small sample size both doses were significantly more effective than the control in achieving earlier passing of the stone. The socioeconomic conditions of Asian countries, and the dietary habits and physical features of Asian people differ greatly from those of Western countries. Many reports have confirmed that low-dose (0.2 mg) tamsulosin is effective in the treatment of BPH in Asian countries, which might be explained by the relatively smaller body weight of Asian patients. 4 -6 Since lowdose tamsulosin is currently used in the treatment of BPH in Asian countries and the results of the present study confirm efficacy of the low dose in Asian patients for the treatment of symptomatic distal ureteric stones, we suggest that low-dose tamsulosin should, perhaps, be used in Asia.
There was a wide range in spontaneous passage of ureteric stones in the present study. The expulsion rate was low (4%) in the control group not given tamsulosin, which is very low for distal ureteric stones with a mean size of 6.70 mm (range 4 -10 mm). However, this group received only sodium diclofenac for 10 days without other medications, based on previous clinical trial procedures. 7 -9 Spontaneous passage of ureteric stones depends on unmodifiable and modifiable factors. The unmodifiable factors are stone size and location, internal anatomical structure, and a history of spontaneous expulsion, whereas the modifiable factors are spasm, oedema and ureteric infection. The aim of medical intervention with anti-spasmodic, antioedemic and antibiotic drugs is to correct the modifiable factors, and to relieve ureteric colic pain until the stone is expelled. 1 The present study is consistent with other studies that have reported a wide range of spontaneous passage rates of ureteric stones, for example where those of size 5 -10 mm had spontaneous passage in 0 -53% of cases. 7, 8 Another study showed that no ureteric stone larger than 6 mm was passed spontaneously. 9 Several studies using animal models have shown the effects of drugs, such as antihistamines, prostaglandins and parasympatholytic agents on ureteric function. 1 To date, several medications, such as calcium channel blockers, corticosteroids, and analgesic and anti-inflammatory drugs have been investigated for the expulsion of distal ureteroliths. 1, 10, 11 Calcium channel blocking agents and steroids have been used to reduce muscle tone and decrease inflammation at the site of the ureteric stone, however, their use in clinical practice is limited due to their potential for serious adverse effects. 2 Evidence has shown the existence of high numbers of α 1 -adrenoceptors in animal and human ureters. In the human ureter, α 1aand α 1d -adrenoceptors are more prevalent than α 1b -adrenoceptors, with the highest density of α 1d -adrenoceptors located in the distal ureter and a lower density found in the middle and proximal ureter. 3 α 1 -Adrenergic antagonists are able to inhibit the basal tone and peristaltic frequency of the ureter, dilating the ureteric lumen and reducing ureteric spasms, thereby facilitating the stone's passage by increasing its rate of transportation. 1 -3 Tamsulosin is a welltolerated combined α 1a -and α 1d -selective adrenergic antagonist. It has also been used B Lojanapiwat, W Kochakarn, N Suparatchatpan et al.
Tamsulosin for distal ureteroliths for the treatment of benign prostatic hyperplasia with minor side effects; dizziness, rhinitis and diarrhoea reported in 14.9%, 13.1% and 6.2% of cases, respectively. 2 Tamsulosin has been used widely in other clinical studies on ureteric stones. For example, Dellabella et al. 12 performed a randomized, prospective study to assess and compare the efficacy of 80 mg phloroglucinol (a weak anticholinergic agent that acts on smooth muscle fibres in a state of spasm), 0.4 mg tamsulosin and 30 mg nifedipine for distal ureteric calculi larger than 4 mm in 210 patients (70 patients in each drug group). All medications were given for a maximum of 28 days. All patients were also given 30 mg deflazacort for 10 days and co-trimoxazole for 8 days. Patients who received tamsulosin had the best expulsion rate, shortest expulsion times and less renal colic pain compared with the other groups. The side-effects were similar for the three medications.
Dellabella et al. 1 also reported on 60 patients whose ureteric stones were located in the juxtavesical ureter. Thirty patients received oral floroglucine-trimetossibenzene and the other 30 patients received 0.4 mg tamsulosin. All patients also received 30 mg deflazacort for 10 days and cotrimoxazole for 8 days. Ultrasound imaging was performed weekly for 4 weeks. The stone expulsion rates were 70% and 100% for floroglucine-trimetossibenzene and tamsulosin, respectively. They concluded that tamsulosin increased stone expulsion rates and decreased expulsion times, thus avoiding endoscopic procedures and hospitalization. Tamsulosin also provided good control of colic pain.
Dellabella et al. 13 assessed the efficacy of adding a corticosteroid drug to tamsulosin in the treatment of distal ureteric calculi. Two groups of 30 patients received 0.4 mg tamsulosin only or 0.4 mg tamsulosin and 30 mg deflazacort, daily. Both groups had similar expulsion rates (90% in the tamsulosin group and 90.7% in the tamsulosin and deflazacort group, P = 0.612), however the addition of a corticosteroid to tamsulosin induced more rapid stone expulsion.
Porpiglia et al. 10 compared the effectiveness of 30 mg deflazacort plus 30 mg slow-release nifedipine with 30 mg deflazacort plus 0.4 mg tamsulosin during watchful waiting management of lower ureteric stones. Both groups received 30 mg deflazacort for a maximum of 10 days and 30 mg nifedipine or 0.4 mg tamsulosin for a maximum of 28 days. Both medical therapies proved to be safe and effective in increasing stone expulsion rate and reducing the need for analgesic therapy; however tamsulosin was more effective than nifedipine at reducing the expulsion time.
In another study, Porpiglia et al. 11 also compared the administration of 0.4 mg/day tamsulosin, 30 mg/day deflazacort, and a combination of these drugs for 10 days in the treatment of symptomatic distal ureteric stones. They concluded that the use of steroids proved effective only when administered with tamsulosin. The expulsion rate was better than those for tamsulosin or steroids alone: 84.8%, 60% and 37.5% for steroid plus tamsulosin, tamulosin only and steroid only, respectively. Tamsulosin alone was an alternative treatment for patients for whom steroid therapy was not suitable.
Tamsulosin has also been used to improve the stone clearance of shock wave lithotripsy for lower ureteric stones. Kupeli et al. 14 reported the benefit of tamsulosin in terms of stone clearance for distal ureteric stones smaller than 5 mm without or with shock B Lojanapiwat, W Kochakarn, N Suparatchatpan et al.
Tamsulosin for distal ureteroliths wave lithotripsy (20%:53.3%), and for distal ureteric stones larger than 5 mm without or with shock wave lithotripsy (33.3%:70.8%).
The study showed significant differences between the stone-free rate for the patients with distal ureteric stones larger than 5 mm with tamsulosin and without tamsulosin (P = 0.019), and significant differences between the tamsulosin and non-tamsulosin groups in conjunction with shock wave lithotripsy (P = 0.0015). The combination of tamsulosin and conventional treatment (oral hydration and sodium diclofenac) for treating distal ureteric stones was especially beneficial for larger stones after shock wave lithotripsy. Gravina et al. 15 reported the advantage of daily adjunctive treatment with tamsulosin for a maximum of 12 weeks after shock wave lithotripsy for renal stones of 4 -20 mm in diameter. After 3 months of follow up, tamsulosin proved to be a safe and effective way to decrease the use of analgesic drugs after shock wave lithotripsy, compared with the control group. This study noted that the mechanism by which fragments were cleared more effectively from the collecting system was not clear. Research has identified α-adrenergic receptors in the ureter, but not in the collecting system.
Resim et al. 16 used tamsulosin for the treatment of steinstrasse at the lower ureter after shock wave lithotripsy in 67 patients. The expulsion rate was not significantly different between the tamsulosin and nontamsulosin groups (65.7% versus 75%, P > 0.05), but 32 patients who received 0.4 mg tamsulosin daily had fewer ureteric colic episodes and less severity of pain. In another study, Yilmaz et al. 17 compared the three different α 1 blockers (tamsulosin, terazosin and doxazosin) for the treatment of distal ureteric stones, and found that there were no differences in efficacy or complications between these drugs.
In conclusion, tamsulosin may be used as first-line therapy for patients with distal ureteric stones of 4 -10 mm. It can increase the number of patients achieving stone-free status and reduce stone expulsion times with minimal side-effects. It also avoids unnecessary complications and the high costs associated with the minimally invasive techniques of shock wave lithotripsy and endourology. Low-dose (0.2 mg/day) and standard-dose (0.4 mg/day) tamsulosin were both found to be effective in treating Asian patients. The results of this study show that low-dose is an acceptable option for use in Asian patients and is worthwhile considering as they tend to have lower mean body weight compared with Western patients.
